Why Does Trientine Cost So Much, and What If My Insurance Won't Cover It?

If you have ever looked at the sticker price of trientine — one of the main treatments for Wilson disease — and felt the floor drop out from under you, you are not alone. Prices in the range of tens of thousands of dollars per month are widely reported by patients in the United States, and the experience of getting insurance to cover it can feel like a second full-time job. Here is an honest explanation of why the drug costs so much, and a practical map of what you can do about it.

Why trientine is so expensive

Trientine is classified as an orphan drug. The Orphan Drug Act, passed in the United States in 1983, was designed to encourage pharmaceutical companies to develop treatments for rare diseases that would otherwise be commercially unviable. In exchange for investing in a drug that serves a small patient population, manufacturers receive years of market exclusivity — effectively a legally protected monopoly — along with tax credits and a faster regulatory path.¹

Wilson disease affects roughly 1 in 30,000 people. The total number of patients who need trientine in the United States at any given time is in the thousands, not the millions. With such a small market, the manufacturer sets a price that recovers development costs and generates profit from a very limited customer base. The result is a per-pill price that can be orders of magnitude higher than drugs used by millions of people.²

This is not unique to Wilson disease. The same economics drive the pricing of treatments for dozens of rare diseases. The system is controversial, and policy debates about it continue — but for now, the price is what it is, and patients need strategies to deal with it.

Trientine formulations and why this matters for cost

There are now multiple forms of trientine. The original trientine dihydrochloride (sold under brand names including Syprine in the US) has been on the market for decades. A newer formulation, trientine tetrahydrochloride (brand name Cuvrior, approved by the FDA in 2022), has also entered the market. Studies show the two salts perform similarly in clinical practice, though direct head-to-head comparison data are still limited.³

The newer formulation was developed with a particular focus on bioavailability and consistency, and in Europe (where it is marketed as Cuprior) it became the first trientine formulation to receive full EMA approval through the standard pathway. A 2024 real-world study of patients switched between formulations found that most managed the transition well, though monitoring during the switch is recommended.⁴

The relevance for cost is that different formulations and different insurance plans may cover one but not the other. If your insurer refuses one, it is worth asking specifically whether the other formulation is on the formulary.

If your insurance denies coverage

Denial of coverage for a high-cost rare disease drug is common, and it is almost never the final word. Here is the sequence most patients find useful:

Step 1: Prior authorization — make the case on the first try

Most insurers require a prior authorization (PA) for expensive specialty medications. Your prescribing physician needs to document medical necessity. This works best when the PA request explicitly states: - Your confirmed Wilson disease diagnosis (with supporting lab results or genetic testing) - That the drug is an established guideline-recommended treatment (the AASLD 2022 guidance explicitly recommends trientine as a first-line option)⁵ - That alternatives either have not worked or are not appropriate for you - The expected consequences of going untreated

A well-documented PA request is significantly more likely to be approved on the first submission than a bare prescription.²

Step 2: Appeal denials

If the PA is denied, you have a right to appeal. Ask your specialist’s office to write a letter of medical necessity. If the insurer’s reviewers are non-specialist physicians, you can request a peer-to-peer review — a phone call between your prescriber and the insurer’s medical reviewer — which sometimes reverses denials.

If internal appeals fail, most states allow external appeals reviewed by independent physicians outside the insurance company. Rare disease advocacy organizations can sometimes help navigate this process.

Step 3: Manufacturer patient assistance programs

Both major trientine manufacturers operate patient assistance programs (PAPs) that can provide the drug free or at reduced cost to patients who qualify financially, or as a bridge while insurance appeals proceed. Contact the manufacturer’s patient support line directly — these programs exist precisely because the sticker price excludes most patients without insurance coverage.²

Copay cards and copay assistance programs (for commercially insured patients) can also reduce out-of-pocket costs even when insurance is covering a portion of the price.

Step 4: Medicaid and state programs

If your income qualifies you for Medicaid, Wilson disease medications are generally covered. Because Wilson disease is a recognized rare disease, coverage is usually obtainable, though prior authorization may still be required. State pharmaceutical assistance programs and state rare disease programs vary — your state health department or a social worker connected to your care team can help identify what exists in your state.

Step 5: Alternative treatments

Penicillamine (d-penicillamine) is a substantially less expensive chelating agent that has been used to treat Wilson disease since the 1950s. It is not the first choice for everyone — it has its own side effect profile that some patients cannot tolerate — but it is effective, guideline-endorsed, and far more accessible in terms of cost for patients without solid coverage.⁵ Zinc acetate or zinc gluconate is even less expensive and is used as a maintenance therapy or for patients who cannot tolerate chelating agents.

If cost is genuinely prohibitive and access to trientine cannot be arranged through the channels above, asking your specialist whether penicillamine or zinc is medically appropriate for your specific situation is a legitimate question, not a compromise you should feel embarrassed to raise.⁶

What about the future?

The landscape is shifting slowly. Generic competition tends to lower orphan drug prices eventually, though the exclusivity periods are long and legal challenges by brand manufacturers can extend them. In the meantime, the Schilsky 2022 AASLD guidance explicitly recognizes access and cost as real issues for Wilson disease patients and calls for advocacy at the health system level.⁵

Patient advocacy organizations — including the Wilson Disease Association in the United States — track drug access issues and can sometimes help patients navigate denials or connect with clinical trials that provide treatment as part of study participation.

See also an overview of all Wilson disease medications for a comparison of the treatment options, and what to tell your doctor for advice on raising cost concerns directly in a clinic visit.

This page provides general information about drug pricing and access strategies. It is not financial or legal advice, and coverage and assistance eligibility vary by insurer, income, and state. Your care team’s social worker or the patient assistance line at the manufacturer are the best starting points for your specific situation.

References